ONdrugDelivery | Global Drug Delivery Industry Information & Intelligence

SUSTAINABILITY

EXCLUSIVE INTERVIEW: TAKING SUSTAINABILITY BEYOND COMPLIANCE

Prof Hanns-Christian Mahler of ten23 Health engages in a wide-ranging discussion about current challenges and trends in the drug delivery industry, particularly on the topic of sustainability – its advantages, difficulties and why companies should aim to do more than the bare minimum required by the regulation.

ECO-DESIGN DRIVING NEST AND READY-TO-USE PACKAGING INNOVATION

Lionel Maritan and François Ciavatti discuss RayDyLyo^®, an eco-designed nest developed to reduce the overall impact of ready-to-use components, reflecting on insights gained from lifecycle assessments, outlining the progress still to be made and illustrating how a pragmatic, inventive, eco-centric design approach can drive the development of packaging solutions with a measurably lower environmental footprint.

CHALLENGES & OPPORTUNITIES TO OPTIMISE SUSTAINABILITY IN PHARMACEUTICAL PACKAGING & COMBINATION DEVICES

Greg Anderson discusses the need to improve the sustainability and circularity of pharmaceutical packaging and drug delivery devices, looking at the challenges and providing a clear outline of the potential opportunities for improvement.

REAL-TIME LCAs: CREATING “A SINGLE SOURCE OF TRUTH” FOR SUSTAINABILITY

REAL-TIME LCAs: CREATING “A SINGLE SOURCE OF TRUTH” FOR SUSTAINABILITY

Serena Grace and Marina Dumont offer insight into the development of a real-time operational model for lifecycle assessments, and detail how organisations can transform these analyses into robust decision-making tools.

MAINTAINING RELIABLE DRUG DELIVERY THROUGH SUSTAINABLE OPERATIONS

MAINTAINING RELIABLE DRUG DELIVERY THROUGH SUSTAINABLE OPERATIONS

Henryk Badack considers how a holistic approach to sustainability can enable CDMOs to implement efficient operations strategically – while introducing initiatives that address environmental, economic and social elements.

LATE-STAGE MATERIAL SUBSTITUTION: AMBITION FOR SUSTAINABILITY OR TRANSFER-TIME RISK?

LATE-STAGE MATERIAL SUBSTITUTION: AMBITION FOR SUSTAINABILITY OR TRANSFER-TIME RISK?

Kiara Taylor delves into the challenges of changing materials to enhance sustainability after a design has been transferred to manufacturing, considering the reasons that might drive such a change, the issues involved and the benefits that can be gained.

BIO-BASED PLASTICS IN DRUG DELIVERY: FROM MATERIAL EQUIVALENCE TO SYSTEMIC DECARBONISATION

Nadine Kaufmann

BIO-BASED PLASTICS IN DRUG DELIVERY: FROM MATERIAL EQUIVALENCE TO SYSTEMIC DECARBONISATION

Nadine Kaufmann and Michael Schori analyse the feasibility of introducing sustainable materials within current regulatory frameworks, demonstrating this with a range of Ypsomed products and illustrating ways to further integrate sustainable principles into the value chain.

SUSTAINABILITY IN DRUG DELIVERY

SUSTAINABILITY IN DRUG DELIVERY

Adam Tilley and David Cook explore how carbon footprint considerations can be integrated into the drug delivery device design lifecycle, highlighting key sustainability decisions faced by design engineers and emerging tools that support those evaluations.

RETHINKING DRUG DELIVERY: ENABLING RECYCLING AND MATERIAL EFFICIENCY IN HEALTHCARE

Dr Bernd Garska

RETHINKING DRUG DELIVERY: ENABLING RECYCLING AND MATERIAL EFFICIENCY IN HEALTHCARE

Dr Bernd Garska and Sven Schlecht highlight how single-use drug delivery devices can be re-thought to help solve the climate and environmental challenges in the healthcare sector.

REINVENTING THE pMDI: EVOLVING A PROVEN PLATFORM FOR A LOW-GWP FUTURE

REINVENTING THE pMDI: EVOLVING A PROVEN PLATFORM FOR A LOW-GWP FUTURE

Chris Baron discusses how lower-global warming potential pressurised metered dose inhalers are moving from development to commercialisation and explains why manufacturing readiness and supply resilience are critical, going on to introduce Aptar Pharma’s ZEN30 Futurity^®, designed to anticipate current and emerging regulatory expectations.

ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS

Markus Laubscher

ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS

Markus Laubscher discusses the role of pressurised metered dose inhalers in the context of healthcare’s drive towards sustainability, considering the need for lower-global-warming-potential propellants and why it is important to preserve these inhalers as a key aspect of respiratory care.

THE PHYSICS OF THE SWITCH: OPTIMISING pMDI DESIGN FOR LOW-CARBON LUNG DELIVERY

THE PHYSICS OF THE SWITCH: OPTIMISING pMDI DESIGN FOR LOW-CARBON LUNG DELIVERY

Thomas Daly and Tony Mallett discuss the transition to low-global warming potential propellants, examining the vital adjustments to the whole inhalation system necessary to support effective and safe dosing without hydrofluorocarbons.

EXPANDING HORIZONS IN LIQUID NASAL DRUG DEVELOPMENT

Catalent Pharma Solutions

EXPANDING HORIZONS IN LIQUID NASAL DRUG DEVELOPMENT

Dr Alan Watts and David Wilcox examine the current product designs in the nasal market landscape and outline key technical and regulatory considerations for liquid nasal drug products.

DE-RISKING DEVICE SELECTION – WHY CHOOSE UNISPRAY FOR NALOXONE RESCUE APPLICATIONS

DE-RISKING DEVICE SELECTION – WHY CHOOSE UNISPRAY FOR NALOXONE RESCUE APPLICATIONS

Elsie Thomas explains why UniSpray is a robust nasal platform for generic naloxone, based on an evidence-driven approach that combines usability studies, threshold analyses and interchangeability assessments, and how it ensures safe and reliable performance, intuitive use, and regulatory acceptability in real-world opioid overdose rescue situations.

A NOVEL HUMAN FACTORS APPROACH FOR A NEW PLATFORM-BASED, BREATH-TRIGGERED NEBULISER

A NOVEL HUMAN FACTORS APPROACH FOR A NEW PLATFORM-BASED, BREATH-TRIGGERED NEBULISER

Simon Bucher, Dr Amy MacDonald and Dr John DeFoggi explain how human factors engineering is at the centre of the development of PARI’s breath-triggered eFlow^® Integrated nebuliser, and consider how this approach preserves scientific rigour while avoiding redundant testing and ensuring efficient resource allocation.

REFRAMING THE ROLE OF NASAL SPRAYS IN AN INCREASINGLY PATIENT-CENTRIC DRUG DELIVERY LANDSCAPE

REFRAMING THE ROLE OF NASAL SPRAYS IN AN INCREASINGLY PATIENT-CENTRIC DRUG DELIVERY LANDSCAPE

Eric Kaneps looks at the reality of nasal drug delivery for liquid formulations and considers how advances not only open new opportunities but can also be seen in the context of a groundswell of momentum around non-invasive, patient-centric delivery. Mr Kaneps reflects on how this shift in dynamics, coupled with a shift in mindset, is opening the door for pharmaceutical companies to expand their drug delivery options and fully optimise the development pathway for their molecule.

HOW SOFT MIST INHALERS WILL BREATHE NEW LIFE INTO DRUG DEVELOPMENT

HOW SOFT MIST INHALERS WILL BREATHE NEW LIFE INTO DRUG DEVELOPMENT

Kasim Yilginc discusses the expanding importance and influence of the respiratory sector within pharmaceutical pipelines, including the role that soft mist inhalers are poised to play in improving patient outcomes and how GAPLAST’s AirlessMotion^® bag-in-bottle technology can support the development of these inhalation devices.

ACOUSTIC WAVE PLATFORM NEBULISER FOR INHALED DELIVERY OF BIOLOGIC THERAPIES

Dr Elijah Nazarzadeh

ACOUSTIC WAVE PLATFORM NEBULISER FOR INHALED DELIVERY OF BIOLOGIC THERAPIES

Dr Elijah Nazarzadeh reports on the applications of Nebu~Flow, an acoustic wave-based nebuliser platform, addressing the challenges associated with drug delivery to the lungs via more efficient aerosolisation, enabling precise inhaled delivery of life-changing treatments.

AUTOMATING MDI ACTUATION: PRECISION DATA WITH LESS EFFORT

Copley Scientific

AUTOMATING MDI ACTUATION: PRECISION DATA WITH LESS EFFORT

Paul Martin considers how automation can enhance testing for metered dose inhalers by removing the variability in actuation technique introduced by manual operation, presenting two case studies that demonstrate this potential improvement in data quality.

INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES

Dr Matthew Owen

INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES

Dr Matthew Owen reviews the formulation and device challenges, designs and considerations that are shaping the nasal delivery market.

MY STERINITY NASAL PLATFORM: A PRODUCT OF COLLABORATION

MY STERINITY NASAL PLATFORM: A PRODUCT OF COLLABORATION

SGD Pharma discusses the advantages and benefits of the company’s recent partnership with Prince Sterilization Services, with a focus on the first product platform developed based on this collaboration – the My Sterinity Nasal platform of Type I glass primary containers for sensitive, long-term nasal therapeutics. Additionally, SGD Pharma highlights its presence at DCAT Week 2026.

THE RETINAL DELIVERY BOTTLENECK: WHY TODAY’S TOOLS WON’T SCALE

Dr David Cottenden

THE RETINAL DELIVERY BOTTLENECK: WHY TODAY’S TOOLS WON’T SCALE

Dr David Cottenden and Benjamin Hatton examine the rapid shift towards cell and gene therapies in ophthalmology, indicated by current pharmaceutical pipelines, and reveal a potential delivery crisis – today’s surgical capacity cannot support what the pipeline demands. Considering this, they explore why a radical rethink of retinal delivery tools could unlock scalable access to the retina.

THE CHALLENGES IN DEVELOPING AND MANUFACTURING CUSTOM OPHTHALMIC INJECTOR DEVICES

Dr Lorna Barron

THE CHALLENGES IN DEVELOPING AND MANUFACTURING CUSTOM OPHTHALMIC INJECTOR DEVICES

Dr Lorna Barron sets out the standards that must be met for effective drug delivery to the eye, characterising both old and new delivery routes that may be used to address the unique challenges of ophthalmic disease.

SHL MEDICAL AND BAYER: A COLLABORATIVE APPROACH TO ADVANCING INTRAVITREAL PAEDIATRIC DOSING

Andreas Kalitzki

SHL MEDICAL AND BAYER: A COLLABORATIVE APPROACH TO ADVANCING INTRAVITREAL PAEDIATRIC DOSING

Andreas Kalitzki, Samuel Wyler and Seda Aksel explain how Bayer and SHL Medical collaborative efforts are enhancing paediatric intravitreal injections through evidence-based dosing strategies and clinically validated therapies using SHL Medical’s Micro Dosing Device technology.

EMPOWERING VISION FOR THE FUTURE: ADVANCED CONTAINMENT SOLUTIONS FOR OPHTHALMIC APPLICATIONS

Dr Linara Cornell

West Pharmaceutical Services

EMPOWERING VISION FOR THE FUTURE: ADVANCED CONTAINMENT SOLUTIONS FOR OPHTHALMIC APPLICATIONS

Dr Linara Cornell, Dr Manali Potnis and Dr Krishnendu Khan review the current landscape and challenges associated with delivery systems for ophthalmic applications, and how West Pharmaceutical Services plays a critical role in this specialised industry by providing high quality prefilled syringe components and systems that meet the stringent requirements for these sight-saving therapies.

NOVELIA<sup>®</sup>: ENABLING THE NEXT GENERATION OF PRESERVATIVE-FREE MULTIDOSE OPHTHALMICS

Séverine Duband

NOVELIA^®: ENABLING THE NEXT GENERATION OF PRESERVATIVE-FREE MULTIDOSE OPHTHALMICS

Severine Duband and Natalia Zabala discuss the role of multidose preservative-free eyedroppers in the ophthalmic market, highlighting the advantages of Nemera’s Novelia^® platform, including its non-return valve system, the sustainability of multidose delivery and the platform’s growing success within the Chinese market.

INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?

INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?

Gregg Draudt considers the significant issue of treatment discontinuation in intravitreal therapies, digging into the root causes of poor adherence and what will be required to reverse this trend in a way that caters to the full range of stakeholders, who often have contradictory requirements.

1
2
3
…
71
Next

See what ondrugdelivery's readers and contributors think

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Top